Skip to main content

Antibacterial Activity and Cyto-/Tissue-Compatibility of Micro-/Nano-Structured Titanium Decorated with Silver Nanoparticles

Buy Article:

$107.14 + tax (Refund Policy)

Implant-associated infections are a major factor contributing to graft failure. Preventing infection by inhibiting bacterial adhesion to implants is critical for successful orthopedic surgery. In this work, we fabricated a novel implant material and evaluated its performance in terms of inhibiting bacterial growth and adhesion. Micro/nano-structured titanium (MNT) was prepared by the micro-arc oxidization. Silver nanoparticles (AgNPs) with an average diameter of 10 nm were synthesized via a chemical reduction method and immobilized onto MNT to generate an AgNP-decorated MNT (AgMN). It showed high antibacterial efficacy against both Escherichia coli and Staphylococcus aureus without cytotoxicity to NIH/3T3 fibroblast-like cells. AgMN implanted in rats inhibited S. aureus growth and adhesion and elicited a milder inflammatory response than MNT. Moreover, implanted AgMN had no adverse effect on the morphology and structure of attached host cells after 1 day. These results indicate that using AgMN as an implant material can reduce the risk of infection without toxic effects to the host.

Keywords: ANTIBACTERIAL; CYTOTOXICITY; INFLAMMATORY RESPONSE; SLIVER NANOPARTICLE; TITANIUM

Document Type: Research Article

Publication date: 01 April 2018

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content